These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 23198277)
1. Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin. Grenader T; Rosengarten O; Isacson R; Plotkin Y; Gabizon A World J Clin Oncol; 2012 Oct; 3(10):137-41. PubMed ID: 23198277 [TBL] [Abstract][Full Text] [Related]
2. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer. Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Power P; Stuart G; Oza A; Provencher D; Bentley JR; Miller WH; Pouliot JF Gynecol Oncol; 2009 Sep; 114(3):410-4. PubMed ID: 19520420 [TBL] [Abstract][Full Text] [Related]
4. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Alberts DS; Liu PY; Wilczynski SP; Clouser MC; Lopez AM; Michelin DP; Lanzotti VJ; Markman M; Gynecol Oncol; 2008 Jan; 108(1):90-4. PubMed ID: 17949799 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of Pegylated Liposomal Doxorubicin in Low-Grade Serous Ovarian Carcinoma. Rose PG; Radeva M; Michener CM; Link N; Adbul-Karim F Int J Gynecol Cancer; 2017 Jun; 27(5):907-911. PubMed ID: 28498259 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer. Rapoport BL; Vorobiof DA; Slabber C; Alberts AS; Hlophe HS; Mohammed C Int J Gynecol Cancer; 2009 Aug; 19(6):1137-41. PubMed ID: 19820382 [TBL] [Abstract][Full Text] [Related]
7. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703 [TBL] [Abstract][Full Text] [Related]
8. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer]. Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568 [TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Kurtz JE; Kaminsky MC; Floquet A; Veillard AS; Kimmig R; Dorum A; Elit L; Buck M; Petru E; Reed N; Scambia G; Varsellona N; Brown C; Pujade-Lauraine E; Ann Oncol; 2011 Nov; 22(11):2417-2423. PubMed ID: 21402619 [TBL] [Abstract][Full Text] [Related]
10. A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy. Huang YF; Kuo MT; Liu YS; Cheng YM; Wu PY; Chou CY Front Oncol; 2019; 9():437. PubMed ID: 31179244 [No Abstract] [Full Text] [Related]
11. Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum-refractory/resistant ovarian cancer. Yoshida H; Fujiwara K Cancer Med; 2023 Jul; 12(13):14196-14206. PubMed ID: 37184128 [TBL] [Abstract][Full Text] [Related]
12. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma. Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935 [TBL] [Abstract][Full Text] [Related]
13. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190 [TBL] [Abstract][Full Text] [Related]
14. Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer. Pignata S; Lauraine EP; du Bois A; Pisano C Crit Rev Oncol Hematol; 2010 Jan; 73(1):23-30. PubMed ID: 19782576 [TBL] [Abstract][Full Text] [Related]
15. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395 [TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience. Lee YJ; Kim YM; Kim HJ; Choi SW; Lee SW; Park JY; Kim DY; Suh DS; Kim JH; Kim YT; Nam JH Obstet Gynecol Sci; 2017 Sep; 60(5):433-439. PubMed ID: 28989919 [TBL] [Abstract][Full Text] [Related]
17. [Pegylated liposomal doxorubicin in ovarian cancer treatment]. Nowak-Markwitz E Ginekol Pol; 2009 Aug; 80(8):615-9. PubMed ID: 19824461 [TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®). Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331 [TBL] [Abstract][Full Text] [Related]
19. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Mahner S; Meier W; du Bois A; Brown C; Lorusso D; Dell'Anna T; Cretin J; Havsteen H; Bessette P; Zeimet AG; Vergote I; Vasey P; Pujade-Lauraine E; Gladieff L; Ferrero A Eur J Cancer; 2015 Feb; 51(3):352-8. PubMed ID: 25534295 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study. Blake EA; Bradley CA; Mostofizadeh S; Muggia FM; Garcia AA; Roman LD; Matsuo K Arch Gynecol Obstet; 2019 Jun; 299(6):1641-1649. PubMed ID: 30824986 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]